- Home
- EBS vs KALV Comparison
EBS vs KALV Comparison
Compare EBS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | KALV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.3M | 551.2M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | EBS | KALV |
|---|---|---|
| Price | $12.55 | $15.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $15.00 | ★ $27.17 |
| AVG Volume (30 Days) | 798.1K | ★ 1.1M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $788,900,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.21 | $204.16 |
| P/E Ratio | $9.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.02 | $7.30 |
| 52 Week High | $13.41 | $17.30 |
Technical Indicators
Market Signals| Indicator | EBS | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 52.76 |
| Support Level | $12.02 | $14.83 |
| Resistance Level | $12.90 | $16.30 |
| Average True Range (ATR) | 0.51 | 0.89 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 73.60 | 30.00 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.